MYOS RENS Technology Inc. (NASDAQ:MYOS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

MYOS RENS Technology (NASDAQ MYOS) traded down 5.37% during trading on Friday, reaching $1.41. The company’s stock had a trading volume of 23,537 shares. MYOS RENS Technology has a 52 week low of $1.02 and a 52 week high of $6.98. The firm has a 50-day moving average price of $1.79 and a 200-day moving average price of $2.45. The firm’s market capitalization is $8.24 million.

WARNING: “ValuEngine Lowers MYOS RENS Technology Inc. (MYOS) to Strong Sell” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with's FREE daily email newsletter.